Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

Clinical trial NCT07136181 · RECRUITING

Trial details

NCT number: NCT07136181
Sponsor: Novelwise Pharmaceutical Corporation
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Uveal Melanoma Uveal Melanoma, Metastatic Uveal Melanoma, Recurrent Eye Cancer, Intraocular Melanoma Eye Cancer

Start date: 2025-11-20
Primary completion: 2028-03-28
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.